Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates
Jayaprakash K. Nair(Alnylam Pharmaceuticals (United States)), Martin A. Maier(Alnylam Pharmaceuticals (United States))
Cited by 264
Related Papers
Rational design of cationic lipids for siRNA delivery
|Nature Biotechnology|2010|1.8k
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
|Nature Nanotechnology|2019|1.6k
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**
|Angewandte Chemie International Edition|2012|1.2k
Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics
|Molecular Therapy|2013|617
Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles
|Molecular Therapy — Nucleic Acids|2013|480